Bag-1 silencing enhanced chemotherapeutic drug-induced apoptosis in MCF-7 breast cancer cells affecting PI3K/Akt/mTOR and MAPK signaling pathways
The multifunctional anti-apoptotic Bag-1 protein has important roles in apoptosis, proteasome-mediated degradation, transcriptional regulation, and intracellular signaling. Bag-1 promotes cell survival and proliferation, and is overexpressed in breast cancer. Therefore, Bag-1-targeted therapy might be a promising strategy to treat breast cancer. However, the effects of Bag-1 silencing in combination with conventional chemotherapeutic drugs on cell viability and major signaling pathways have not yet been fully investigated in breast cancer cells. In this study, we investigated the cytotoxic effects of Bag-1 silencing, alone and in combination with cisplatin or paclitaxel treatment, in MCF-7 breast cancer cells. Bag-1 knockdown by shRNA or siRNA transfection sensitized MCF-7 cells to apoptosis induced by cisplatin or paclitaxel. Combination of Bag-1 silencing and drug treatment more potently downregulated the pro-survival PI3K/Akt/mTOR and p44/42 mitogen activated protein kinase (MAPK) pathways, and more potently upregulated the stress-activated p38 and SAPK/JNK MAPK pathways. Bag-1-silenced drug-treated cells had also highly reduced proliferative capacity, downregulated cyclin–cyclin dependent kinase complexes and upregulated tumor suppressors p21 and Rb. These results overall indicated that Bag-1 silencing enhanced cisplatin- or paclitaxel-induced cytotoxicity through multiple pathways. In conclusion, Bag-1 targeted therapy might enhance the therapeutic potential of conventional anti-cancer drugs in the treatment of breast cancer.
KeywordsBag-1 siRNA/shRNA Chemotherapeutic agents Apoptosis Breast cancer MAPK PI3K/Akt/mTOR pathway
This work was supported by internal funds of Istanbul Technical University and Istanbul Kultur University Scientific Project Support Centers.
Compliance with ethical standards
Conflict of interest
Authors declare that there is no conflict of interest.
Research involving human participants and/or animals
There are no human participants and/or animals used in this study.
- 2.Fischgrabe J, Wulfing P (2008) Targeted therapies in breast cancer: established drugs and recent developments. Curr Clin Pharmacol 3(2):85–98Google Scholar
- 3.Li QQ, Wang G, Liang H, Li JM, Huang F, Agarwal PK et al (2013) Beta-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas. Anticancer Res 33(4):1421–1428Google Scholar
- 4.Niknafs B (2011) Induction of apoptosis and non-apoptosis in human breast cancer cell line (MCF-7) by cisplatin and caffeine. Iran Biomed J 15(4):130–133Google Scholar
- 5.Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A et al (2014) Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev 15(8):3353–3358Google Scholar
- 12.Brazil DP, Hemmings BA (2001) Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 26(11):657–664Google Scholar
- 14.Cai Y, Tan X, Liu J, Shen Y, Wu D, Ren M et al (2014) Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Chin J Cancer Res 26(5):564–572. https://doi.org/10.3978/j.issn.1000-9604.2014.08.20 Google Scholar
- 16.Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH et al (2002) The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80(2):239–256Google Scholar
- 17.Troppmair J, Bruder JT, Munoz H, Lloyd PA, Kyriakis J, Banerjee P et al (1994) Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation. J Biol Chem 269(9):7030–7035Google Scholar
- 18.Lavoie JN, L’Allemain G, Brunet A, Muller R, Pouyssegur J (1996) Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271(34):20608–20616Google Scholar
- 20.Xu R, Sato N, Yanai K, Akiyoshi T, Nagai S, Wada J et al (2009) Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. Anticancer Res 29(1):261–270Google Scholar
- 27.Bardelli A, Longati P, Albero D, Goruppi S, Schneider C, Ponzetto C et al (1996) HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 15(22):6205–6212Google Scholar
- 28.Packham G, Brimmell M, Cleveland JL (1997) Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation. Biochem J 328(Pt 3):807–813Google Scholar
- 30.Yang X, Hao Y, Ding Z, Pater A, Tang SC (1999) Differential expression of antiapoptotic gene BAG-1 in human breast normal and cancer cell lines and tissues. Clin Cancer Res 5(7):1816–1822Google Scholar
- 31.Liu H, Liang Y, Li Y, Li Y, Wang J, Wu H et al (2010) Gene silencing of BAG-1 modulates apoptotic genes and sensitizes lung cancer cell lines to cisplatin-induced apoptosis. Cancer Biol Ther 9(10):832–840Google Scholar
- 34.Janicke RU, Ng P, Sprengart ML, Porter AG (1998) Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 273(25):15540–15545Google Scholar
- 35.Leggett S, Koczwara B, Miller M (2015) The impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer—a systematic review. Nutr Cancer 67(3):373–391. https://doi.org/10.1080/01635581.2015.1004731 Google Scholar
- 38.Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S, Wang HG et al (1998) Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat 47(2):129–140Google Scholar
- 39.Rorke S, Murphy S, Khalifa M, Chernenko G, Tang SC (2001) Prognostic significance of BAG-1 expression in nonsmall cell lung cancer. Int J Cancer 95(5):317–322Google Scholar
- 40.Shindoh M, Adachi M, Higashino F, Yasuda M, Hida K, Nishioka T et al (2000) BAG-1 expression correlates highly with the malignant potential in early lesions (T1 and T2) of oral squamous cell carcinoma. Oral Oncol 36(5):444–449Google Scholar
- 43.Tolcher AW (1996) Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Semin Oncol 23(1 Suppl 1):37–43Google Scholar
- 44.Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96(8):4240–4245Google Scholar
- 46.Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14(5):381–395Google Scholar
- 51.Dotto GP (2000) p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 1471(1):M43–M56Google Scholar